[go: up one dir, main page]

GB0128898D0 - Materials and methods relating to the stabilization and activation of a tumour suppressor protein - Google Patents

Materials and methods relating to the stabilization and activation of a tumour suppressor protein

Info

Publication number
GB0128898D0
GB0128898D0 GBGB0128898.4A GB0128898A GB0128898D0 GB 0128898 D0 GB0128898 D0 GB 0128898D0 GB 0128898 A GB0128898 A GB 0128898A GB 0128898 D0 GB0128898 D0 GB 0128898D0
Authority
GB
United Kingdom
Prior art keywords
stabilization
activation
materials
methods relating
suppressor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0128898.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Research Ventures Pte Ltd
Original Assignee
Biotech Research Ventures Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Research Ventures Pte Ltd filed Critical Biotech Research Ventures Pte Ltd
Priority to GBGB0128898.4A priority Critical patent/GB0128898D0/en
Publication of GB0128898D0 publication Critical patent/GB0128898D0/en
Priority to US10/497,564 priority patent/US7459282B2/en
Priority to AU2002365661A priority patent/AU2002365661A1/en
Priority to EP02804299A priority patent/EP1465651A1/en
Priority to PCT/GB2002/005440 priority patent/WO2003047613A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
GBGB0128898.4A 2001-12-03 2001-12-03 Materials and methods relating to the stabilization and activation of a tumour suppressor protein Ceased GB0128898D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0128898.4A GB0128898D0 (en) 2001-12-03 2001-12-03 Materials and methods relating to the stabilization and activation of a tumour suppressor protein
US10/497,564 US7459282B2 (en) 2001-12-03 2002-12-03 Use of c-Jun or c-Jun activating agents such as UV or c-Jun N-terminal kinases (JNKs) for treating cancer
AU2002365661A AU2002365661A1 (en) 2001-12-03 2002-12-03 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
EP02804299A EP1465651A1 (en) 2001-12-03 2002-12-03 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
PCT/GB2002/005440 WO2003047613A1 (en) 2001-12-03 2002-12-03 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128898.4A GB0128898D0 (en) 2001-12-03 2001-12-03 Materials and methods relating to the stabilization and activation of a tumour suppressor protein

Publications (1)

Publication Number Publication Date
GB0128898D0 true GB0128898D0 (en) 2002-01-23

Family

ID=9926901

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0128898.4A Ceased GB0128898D0 (en) 2001-12-03 2001-12-03 Materials and methods relating to the stabilization and activation of a tumour suppressor protein

Country Status (5)

Country Link
US (1) US7459282B2 (en)
EP (1) EP1465651A1 (en)
AU (1) AU2002365661A1 (en)
GB (1) GB0128898D0 (en)
WO (1) WO2003047613A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (en) * 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 Be used for the method and composition based on MicroRNA of diagnosis, prognosis and the treatment of breast cancer
ES2523989T3 (en) * 2005-09-12 2014-12-03 The Ohio State University Research Foundation Compositions for the therapy of cancers associated with BCL2
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
EP2479285B1 (en) 2006-01-05 2014-05-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
JP5451077B2 (en) 2006-01-05 2014-03-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA-based methods and compositions for lung cancer diagnosis, prognosis and treatment
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
US7985584B2 (en) 2006-03-20 2011-07-26 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
ES2447850T3 (en) 2006-07-13 2014-03-13 The Ohio State University Research Foundation Methods and compositions based on micro-RNA for the prognosis and treatment of diseases related to the colon
JP5426383B2 (en) * 2006-09-19 2014-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション TCL1 expression regulated by miR-29 and miR-181 in chronic lymphocytic leukemia
JP5501766B2 (en) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA expression signature to predict survival and metastasis in hepatocellular carcinoma
AU2008211142A1 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
EP2610347B1 (en) * 2007-04-30 2015-04-15 The Ohio State University Research Foundation Methods of determining the prognosis of a subject with pancreatic cancer
EP2559773B1 (en) * 2007-06-08 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods for determining a hepatocellular carcinoma subtype
EP2167521A4 (en) * 2007-06-15 2011-11-23 Univ Ohio State Res Found ALL-1 ONCOGEN FUSION PROTEINS TO TARGE TREATMENT OF MICRO-RNA REGULATED BY DROSHA
CA2695184A1 (en) * 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
JP2010535473A (en) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン Superconserved region encoding ncRNA
CA2696887C (en) * 2007-08-22 2016-06-28 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CA2702241A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHODS FOR IDENTIFYING INTERACTION OF THE "FRAGILE HISTIDINE TRIAD" GENE (FHIT) AND USES THEREOF
US20100323357A1 (en) * 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
ES2600165T3 (en) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation MiR-32 antagonists to increase the response of prostate cancer to apoptosis
JP2011517932A (en) * 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010059779A1 (en) * 2008-11-21 2010-05-27 The Ohio State University Research Foundation Tcl1 AS A TRANSCRIPTIONAL REGULATOR
JP5960060B2 (en) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ Substances and methods useful for influencing tumor cell growth, migration and invasion
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
EP2640368B1 (en) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Controlled release mucoadhesive systems
CN103561750A (en) 2011-03-07 2014-02-05 俄亥俄州立大学 Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
CN104364390B (en) 2011-10-14 2016-08-24 俄亥俄州立大学 Methods and materials related to ovarian cancer
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
CA2866052A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
CN109777779B (en) * 2019-01-02 2019-10-08 广东医科大学 A method of establishing colorectal cancer p73 reporter gene cell line

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603156A1 (en) * 1986-02-03 1987-08-06 Zeiss Carl Fa DEVICE FOR THERAPEUTIC RADIATION OF ORGANIC TISSUE WITH LASER RADIATION
WO1994009363A1 (en) * 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Cancer diagnosis and therapy
EP0599077A3 (en) * 1992-10-29 1994-11-23 Yeda Res & Dev Anti-metastatic vaccine.
JPH0956836A (en) * 1995-08-29 1997-03-04 Mitsubishi Rayon Co Ltd Cancer treatment equipment
WO1999066946A1 (en) * 1998-06-24 1999-12-29 Trustees Of The University Of Pennsylvania Compositions and methods for inducing apoptosis in e6-expressing cells

Also Published As

Publication number Publication date
US7459282B2 (en) 2008-12-02
AU2002365661A1 (en) 2003-06-17
US20060127895A1 (en) 2006-06-15
EP1465651A1 (en) 2004-10-13
WO2003047613A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
GB0128898D0 (en) Materials and methods relating to the stabilization and activation of a tumour suppressor protein
EP1546112A4 (en) Imidazolopyridines and methods of making and using the same
IL164295A0 (en) Tri-substituted heteroaryls and methods of making and using the same
GB0202633D0 (en) Stabilization of protein preparations
GB0112699D0 (en) Process for the preparation of prostglandins and analogues thereof
IL157142A0 (en) Modified antibodies and methods of use
IL164780A0 (en) Substituted phenylacetamides and their use as glucokinase activators
IL195076A0 (en) Improved skin substitutes and uses thereof
EP1497270A4 (en) Amide compounds and methods of using the same
GB2392644B (en) Structured material and method of producing the same
GB0402099D0 (en) Method of attaching hair-thickening hair material and hair-thickening hair material fixture used for the method
IL159215A0 (en) A solution of interleukin-13 and methods utilizing the same
AU6395201A (en) Tumour suppressor and uses thereof
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2003246614A8 (en) Novel use of lipopeptide preparations
EP1432448A4 (en) Novel molecules of the hkid-1-related protein family and uses thereof
AU5565401A (en) Materials and methods for the treatment of depression
AU2002311620A1 (en) Methods of making and using expression constructs for the expression of recombinant proteins
IL162014A0 (en) Shape-recovering material suitable for application of an attachment, and its use
GB0201025D0 (en) The treatment of degenerative diseases
IL161598A0 (en) Use of chitosan materials
AU2002340437A1 (en) Crystals and structures of yiim proteins
AU2002320621A1 (en) Structural and cytoskeleton-associated proteins

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)